In the News

A student at GAP-Net site Northwestern University created Alzheimer’s Brain Box, a customized box to help engage the brain and enhance mood for those living with the disease. Weinberg second-year student Victoria Da Conceicao learned at a young age what it means to fight back against adversity. As a child, she always lived near her […]

GAP-Net site Princeton Medical Institute’s Dr. Jeffrey Apter was featured on NJ 101.5 and spoke about an Alzheimer’s drug that is taking a fresh approach on treating the disease. We’ve heard it called the long goodbye. I can only imagine how painful it is to have your parents go through the slow decline of dementia, […]

Research from GAP-Net site University of California, San Francisco finds retinal scans tie blood vessel deterioration to APOE4, the most prevalent genetic risk for Alzheimer’s disease. While it has been said that the eyes are a window to the soul, a new study shows they could be a means for understanding diseases of the brain. […]

The Bio-Hermes study will not close until 20% of its volunteers are Hispanic/Latinx, and/or African American/Black. This article is also available in Spanish. A clinical trial could lead to the creation of biomarker-based rapid Alzheimer’s tests. The research called Biohermes will include older Hispanics in the study, announced the Global Alzheimer’s Platform Foundation (GAP). The study will be carried out in […]

GAP-Net site, Inland Northwest Research, and GAP President, John Dwyer, talk about the Parkinson’s disease study, PADOVA, and what it hopes to achieve. A Parkinson’s disease clinical trial is launching at 120 global sites – including Spokane – to do a broader test of an investigational drug that in an earlier phase indicated it slowed […]

GAP-Net site, Clarity Clinical Research, was featured on CNYCentral about their participation in the Bio-Hermes study. Clarity Clinical Research, a Syracuse research group, is looking for volunteers in an Alzheimer’s risk study. The study includes three visits with no-cost amyloid PET scans that are designed to predict or possibly diagnose Alzheimer’s disease. Brain amyloid plaques […]

GAP President John Dwyer was on RochesterFirst.com to talk about the ground breaking Bio-Hermes study and what it means for the future of Alzheimer’s detection. Click here to watch the full interview.  In the next few years – we could expect Alzheimer’s detection to be as easy and accessible as ordering up a blood test, […]

GAP President John Dwyer spoke to Alzforum about the Bio-Hermes study. With disease-modifying treatments for Alzheimer’s disease potentially on the cusp of approval, there will be pressing demand for quick, simple ways to screen patients and determine if they have amyloid plaque in their brains. The current gold-standard diagnostics used in research—amyloid PET scans and […]

GAP-Net Site Clarity Clinical Research talks about their participation in GAP’s Bio-Hermes Study. Syracuse, N.Y. — A Syracuse research clinic is seeking volunteers for a brain scan that may help predict or diagnose Alzheimer’s disease before symptoms appear. Clarity Clinical Research is one of 10 clinics nationwide offering no cost Amyloid PET scans as part […]

GAP President John Dwyer was quoted in a New York Times article along side three Alzheimer’s volunteer participants in the donanemab clinical trial by Lilly, a GAP partner. Despite the urgent need for treatments to slow or stop Alzheimer’s disease, finding patients for clinical trials has been difficult and frustrating. Patients are often older. Their […]

Lilly, AbbVie, Merck, the Alzheimer’s Drug Discovery Foundation, and leading technology companies join the first platform study assessing various biomarker tests’ ability to predict the presence of Alzheimer’s Contact: Pamela Larkin – pamelalarkin@rational360.com, 408-466-5952 Washington, DC (April 20, 2021) – Today, the Global Alzheimer’s Platform Foundation® (GAP) announced eleven biopharma, technology, and nonprofit partners who […]

GAP-Net site Inland Northwest Research LLC screened the first patient in the Roche PADOVA study for an investigational Parkinson’s disease drug. Spokane, Washington (April 12, 2021) – Inland Northwest Research, LLC screened the first patient worldwide for the Parkinson’s Disease PADOVA study. The Global Alzheimer’s Platform Foundation® (GAP) is helping study sponsor Roche (SIX: ROG) […]

GAP President John Dwyer wrote to the FDA in support of the Aducanumab drug developed by Biogen. Dear Dr. Woodcock, On behalf of the Global Alzheimer’s Platform Foundation (GAP) and millions of Alzheimer’s patients and caregivers across the nation, I urge the Food and Drug Administration (FDA) to approve aducanumab for treatment of early stage […]

GAP-Net site USF Health has received a grant from the NIH to study a computerized brain training exercise, and if it can reduce the disk of Alzheimer’s disease and other dementias. The National Institutes of Health (NIH) has awarded the University of South Florida (USF) total expected funds of $44.4 million over the next five […]

GAP-Net Site KU ADC has received over $1.3 million to research how exercise supports the brain as humans age. TOPEKA, Kan. (WIBW) – The University of Kansas Alzheimer’s Disease Center has received over $1 million to research how exercise could prevent Alzheimer’s. Senator Roger Marshall (R-Kan.) says the University of Kansas Alzheimer’s Disease Center has […]

GAP-Net site Kansas University ADC was granted $4.3 million from the NIH to elevate dementia care in Kansas communities. Dementia researchers are convinced the path to beating back the life-robbing disease goes directly through clinical trials fueled by research volunteers willing to join the battle. That’s why the experts at the University of Kansas Alzheimer’s Disease […]

GAP President John Dwyer speaks about GAP’s participation in the original Trailblazer trial, and our goals for TRAILBLAZER-ALZ 2. It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite some positive signals from […]

GAP-Net site Knight ADRC at Washington University in St. Louis received two grants to determine whether driving changes can identify people with mild and very mild cognitive impairment, and maybe even identify people in the earliest stage of Alzheimer’s disease. Every day in the U.S. in 2018, motor vehicle crashes killed more than 20 people […]

TRAILBLAZER-ALZ 2 is the second study of donanemab, which showed favorable results in an earlier trial. Washington, DC (March 13, 2021) – Eli Lilly and Company, a leader in Alzheimer’s research for over 30 years, is partnering with the Global Alzheimer’s Platform Foundation® (GAP) to accelerate recruitment services and expand the number of clinical research […]

GAP-Net Site, The Cognitive and Research Center of New Jersey, talks about their participation in the GREEN MEMORY trial. The Alzheimer’s Drug, Oligomannate, approved in China and derived from seaweed, is now being studied in the U.S. in a Phase 3, multi-center clinical trial that is actively recruiting participants.  Oligomannate, a drug made from seaweed […]

GAP President John Dwyer spoke about the Green Valley clinical trial’s success in China, which is now being tested in North America. A new drug extracted from seaweed and inspired by traditional Chinese medicine has come to the United States, where researchers hope it will provide the breakthrough in Alzheimer’s treatment that has eluded us […]

GAP Chairman, George Vradenburg, and The Women’s Alzheimer’s Movement founder, Maria Shriver, co-wrote a piece on what the Biden Administration needs to do to start fulfilling their promises made to Alzheimer’s patients and researchers. No president has entered the White House with as clear a focus on Alzheimer’s disease as Joe Biden. The commitment and […]

GAP-Net site Clarity Clinical Research issued the first treatment to volunteer Mark Cornue in the GREEN MEMORY study. Last week, Clarity Clinical Research administered the first research treatment in the world for the Green Memory study to Mark Cornue, a local Jordan resident and Alzheimer’s patient. The Green Memory study is a noninvasive Alzheimer’s disease clinical trial […]

GAP-Net site Kerwin Medical Center’s Citizen Scientist, Dominic Morello, a caregiver for his father with Alzheimer’s, wrote an Op-Ed on how this generations Alzheimer’s patients can make the disease a thing of the past. There are more than 100 potential Alzheimer’s treatments in the pipeline, but the majority of clinical trials for potential Alzheimer’s therapies are delayed due to enrollment […]